| Literature DB >> 6400035 |
Abstract
Clinical trials with IFN-alpha, produced from buffy coats of leukocytes, have been going on at Radiumhemmet, Karolinska Hospital since 1969. In some of the benign and malignant tumor diseases studied, IFN has been shown to induce regressions. In the case of the benign tumor juvenile laryngeal papillomatosis, IFN has been shown to be superior to other treatment modalities. So far IFN has not been shown to be superior to conventional treatment in any of the malignant tumors studied.Entities:
Mesh:
Substances:
Year: 1984 PMID: 6400035 DOI: 10.1007/BF02934980
Source DB: PubMed Journal: Med Oncol Tumor Pharmacother ISSN: 0736-0118